July 26, 2012
Bristol-Myers Squibb bypasses loan market in Amylin deal
By Michelle Sierra
Bristol-Myers Squibb Co is bypassing the loan market altogether and tapping the bond market directly as part of its funding strategy for the $5.3 billion acquisition of Amylin Pharmaceuticals Inc...
If you already have a OnePass account, you can use it to access Business Law Currents as part of our free trial
program. If you don’t have a OnePass account, click on the link to the left to create one. You can then use this
OnePass account to access Business Law Currents as part of our free trial.